FCG Investment Co Makes New Investment in Stryker Corporation $SYK

Key Points

• FCG Investment Co has acquired a new stake in Stryker Corporation, purchasing 3,769 shares valued at approximately $1.4 million during the 1st quarter.
• Several major institutional investors, including GAMMA Investing LLC and Vanguard Group Inc., have significantly increased their holdings in Stryker, which now has 77.09% of its stock owned by institutional investors.
• Stryker announced a quarterly dividend of $0.84 per share to be paid on October 31st, representing an annual yield of 0.9% and a payout ratio of 44.50%.

FCG Investment Co purchased a new stake in shares of Stryker Corporation (NYSE:SYK - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,769 shares of the medical technology company's stock, valued at approximately $1,403,000.

Several other institutional investors also recently added to or reduced their stakes in SYK. Capital A Wealth Management LLC bought a new position in Stryker during the fourth quarter worth about $26,000. Goodman Advisory Group LLC bought a new stake in Stryker during the first quarter valued at approximately $32,000. City Holding Co. lifted its position in Stryker by 528.6% during the first quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after purchasing an additional 74 shares during the last quarter. Smallwood Wealth Investment Management LLC bought a new stake in Stryker during the first quarter valued at approximately $40,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in shares of Stryker in the 4th quarter valued at $42,000. Institutional investors own 77.09% of the company's stock.

Stryker Price Performance

SYK traded up $8.3540 during trading on Tuesday, reaching $389.9640. 1,691,504 shares of the company traded hands, compared to its average volume of 1,344,400. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19. The firm has a fifty day simple moving average of $386.87 and a 200 day simple moving average of $379.45. The company has a market cap of $149.09 billion, a P/E ratio of 51.65, a PEG ratio of 2.77 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. During the same period last year, the firm posted $2.81 EPS. The company's revenue was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, equities analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker's dividend payout ratio (DPR) is 44.50%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Evercore ISI upped their price objective on shares of Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Sanford C. Bernstein set a $450.00 price objective on shares of Stryker in a research report on Monday, May 5th. Truist Financial set a $415.00 target price on shares of Stryker and gave the company a "hold" rating in a report on Monday, August 4th. Wells Fargo & Company boosted their target price on shares of Stryker from $435.00 to $445.00 and gave the company an "overweight" rating in a report on Friday, August 1st. Finally, Citigroup reiterated a "buy" rating and issued a $455.00 price target (up previously from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. Fifteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $430.10.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares of the company's stock, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 5.20% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.